Litcius/Paper detail

Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase

Nawaf A. Alsaif, Alaa Elwan, Mohammed M. Alanazi, Ahmad J. Obaidullah, Wael A. Alanazi, Abdullah F. Alasmari, Hussam Albassam, Hazem A. Mahdy, Mohammed S. Taghour

2021Molecular Diversity24 citationsDOI

Topics & Concepts

SorafenibCytotoxicityQuinoxalineIC50Docking (animal)ChemistryStereochemistryCytotoxic T cellIn vitroKinaseKinase insert domain receptorBiochemistryPharmacologyVEGF receptorsBiologyVascular endothelial growth factorCancer researchVascular endothelial growth factor AOrganic chemistryMedicineNursingHepatocellular carcinomaSynthesis and Biological EvaluationQuinazolinone synthesis and applicationsSynthesis and biological activity
Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase | Litcius